《大行》里昂升中生制药(01177.HK)目标价至7元 维持“跑赢大市”

阿斯达克财经
Jun 13, 2025

里昂研究报告指,中国生物制药(01177.HK) 日前在投资者会议上透露,与多间跨国制药公司达成多项对外授权协议,包括一个即将落实的重点项目。基于丰富的研发管道,公司预期商业拓展(BD)交易的款项将于2025年起成为恒常的盈利来源。展望未来,公司预计每年会推出5种以上的新分子新药,令其创新产品组合将于2027年增加至30种以上。该行将中生制药2026及27年的收入预测分别上调10.2%及3.9%,...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10